Education
About Us
Working with TipRanks
Follow Us
Rezolute (RZLT)
NASDAQ:RZLT
RZLT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.22 - $9.56
Previous CloseN/A
Volume107.87K
Average Volume (3M)1.27M
Market Cap
$856.35M
Enterprise Value$254.51M
Total Cash (Recent Filing)$167.86M
Total Debt (Recent Filing)$1.61M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Nov 06, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding90,811,370
10 Day Avg. Volume1,964,692
30 Day Avg. Volume1,266,122
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio-4.91
Enterprise Value/Market Cap0.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.21K
Enterprise Value/Ebitda-3.23
Forecast
1Y Price Target
$14.33Price Target Upside55.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Clinical DataPositive data from an expanded access program of ersodetug in patients with tumor-induced hyperinsulinism suggest the treatment could be more efficacious than typical therapies.
ManagementThe company appointed Dr. Sunil Karnawat as Chief Commercial Officer, who has over 25 years of experience in global commercialization and has been involved in launching four products for ultra-rare diseases.
Regulatory AlignmentRezolute announced that it reached alignment with the FDA on its other ersodetug P3 program ('upLIFT'), in tumor hyperinsulinism, whereby the trial is being reduced to n=16 open-label, rather than the initially planned larger, double-blind, placebo controlled study.
Bears Say
Capital RaisingRezolute is likely to need to raise additional capital.
Financial NeedsRezolute is not generating revenue and has capital needs that exceed current cash balance.
Study DesignThe study's original design included a double-blind arm, which would have provided more robust data but has been removed in the new alignment.
Rezolute News
RZLT FAQ
What was Rezolute’s price range in the past 12 months?
Rezolute lowest stock price was $2.21 and its highest was $9.56 in the past 12 months.
What is Rezolute’s market cap?
Rezolute’s market cap is $856.35M.
When is Rezolute’s upcoming earnings report date?
Rezolute’s upcoming earnings report date is Nov 06, 2025 which is in 34 days.
How were Rezolute’s earnings last quarter?
Rezolute released its earnings results on Sep 17, 2025. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.219 by -$0.041.
Is Rezolute overvalued?
According to Wall Street analysts Rezolute’s price is currently Undervalued.
Does Rezolute pay dividends?
Rezolute does not currently pay dividends.
What is Rezolute’s EPS estimate?
Rezolute’s EPS estimate is -0.25.
How many shares outstanding does Rezolute have?
Rezolute has 90,811,370 shares outstanding.
What happened to Rezolute’s price movement after its last earnings report?
Rezolute reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.219. Following the earnings report the stock price went up 6.355%.
Which hedge fund is a major shareholder of Rezolute?
Currently, no hedge funds are holding shares in RZLT
Rezolute Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.33 (55.93% Upside)
$14.33 (55.93% Upside)
Blogger Sentiment
Bullish
RZLT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 25.8%
Last 30 Days ▲ 25.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
105.44%
12-Months-Change
Fundamentals
Return on Equity
-52.56%
Trailing 12-Months
Asset Growth
32.21%
Trailing 12-Months
Company Description
Rezolute
Rezolute, Inc. (RZLT) is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and orphan diseases. The company is primarily engaged in the research and development of innovative treatments targeting serious conditions such as rare metabolic disorders. Its core product candidates include RZ358, an antibody designed to treat congenital hyperinsulinism, and RZ402, an oral therapy aimed at diabetic macular edema.
RZLT Stock 12 Month Forecast
Average Price Target
$14.33
▲(55.93% Upside)
Technical Analysis
Ownership Overview
11.14% Insiders
38.11% Mutual Funds
36.15% Other Institutional Investors
7.38% Public Companies and Individual Investors